Myanmar's military junta has created a challenging currency system, making the foreign-exchange market difficult for traders. Despite the odds, one local trader has achieved a remarkable 22% return on the volatile kyat, though his success is questionable given the lack of significant counterparties in the market.
The Italian pharmaceutical sector, particularly equivalent medicines, has saved the National Health Service approximately €6.25 billion since 2012, enhancing access to affordable care. Undersecretary Marcello Gemmato emphasized the need for supportive policies to foster innovation and investment, while addressing challenges like payback mechanisms that impact pharmaceutical companies. With a production value of €52 billion, Italy stands as a leader in European pharmaceutical innovation, crucial for both economic growth and public health advancements.
UBS has maintained a "Neutral" rating for Nokia with a target price of 3.55 euros following the company's third-quarter results, which fell short of sales expectations. Analyst Francois-Xavier Bouvignies noted that while the operating result met forecasts due to a favorable product mix and cost-cutting, the company's annual targets appear more pessimistic, suggesting a slight decline in consensus estimates for the operating result.
15:19 17.10.2024
UBS has maintained a 'Neutral' rating for Nokia, setting a price target of 3.55 euros following the company's third-quarter results, which fell short of sales expectations. Despite this, the operating result aligned with forecasts due to effective cost management and product mix adjustments. Analysts anticipate a slight decline in consensus estimates for the operating result amid more cautious annual targets.
15:19 17.10.2024
The European Central Bank has lowered the deposit rate to 3.25% and the refinancing rate to 3.40%, marking the third consecutive cut amid slowing inflation. In the US, retail sales rose by 0.4%, surpassing expectations, while initial jobless claims fell to 241,000, offering a glimmer of hope for the economy. Investors are eyeing the 19,700-point level on the DAX, with the 19,500-point mark as a key support.
IG
15:18 17.10.2024
In the inaugural episode of Checkpoint HealthTech, host Jan Thomas discusses the digital healthcare sector with investors Hendrik Steenfadt and Johannes Blaschke. They explore the slow pace of innovation in healthcare, the influence of major tech companies, and the challenges startups face, particularly in Europe where large exits remain rare. The conversation highlights the potential of technologies in prevention and telemedicine, emphasizing the sector's appeal to investors despite its hurdles.
UBS has maintained a "Neutral" rating on Nestlé with a price target of 91 francs following the analysts' conference on quarterly figures. The company anticipates a further decline in operating margin for 2025, which, along with a revised outlook for 2024, is expected to lower consensus earnings estimates. Nestlé has not reiterated its growth forecast for organic sales but aims to outpace industry growth.
15:13 17.10.2024
UBS has maintained a "Neutral" rating on Nestlé with a target price of 91 francs following the analysts' conference on quarterly figures. The food manufacturer anticipates a further decline in operating margin for 2025, which, along with a revised outlook for 2024, is expected to lower consensus earnings estimates. Nestlé has not reiterated its growth forecast for sales from its own resources but aims to outpace industry growth.
15:13 17.10.2024
UBS has maintained a 'Neutral' rating on Nestlé, setting a price target of 91 francs following the recent analyst conference. The food manufacturer anticipates a further decline in its operating margin for 2025, which, along with a revised outlook for 2024, is expected to lower consensus earnings estimates. Nestlé has not reiterated its growth forecast for sales from its own resources but aims to outpace industry growth.
15:13 17.10.2024
UBS has raised its price target for Vertex Pharmaceuticals to $562 from $477, maintaining a Buy rating after resuming coverage. The firm highlights Vertex's strong growth in its core Cystic Fibrosis business and anticipates significant potential for suzetrigine, a novel non-opioid pain medication, estimating over $10 billion in long-term market potential.
15:02 17.10.2024
Trending
Subcategory:
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings